CHIMERIC THERAPEUTIC ORDINARY (CHM) Short Interest
CHIMERIC THERAPEUTIC ORDINARY (ASX:CHM) had 0.00% of shares reported as short positions as of 11 July 2026, representing 1 shares. CHIMERIC THERAPEUTIC ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Unlock advanced features: Custom dashboards, portfolio tracking, real-time alerts, and more
Chimeric Therapeutics
Chimeric Therapeutics is an Australian clinical-stage cell therapy company focused on developing and commercializing innovative cell therapies for cancer patients. Their diversified portfolio includes autologous CAR T-cell therapies and allogeneic NK cell therapies, targeting multiple oncology disease areas. The company currently has several clinical trials underway.